BTIG Research Issues Pessimistic Forecast for Humacyte (NASDAQ:HUMA) Stock Price

Humacyte (NASDAQ:HUMA) had its price target dropped by equities research analysts at BTIG Research from $6.00 to $3.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s price target would suggest a potential upside of 344.05% from the company’s current price.

Several other brokerages have also recently weighed in on HUMA. Benchmark dropped their target price on Humacyte from $11.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, January 21st. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of Humacyte in a research note on Monday, December 1st. Wall Street Zen downgraded Humacyte from a “hold” rating to a “sell” rating in a research report on Sunday, December 21st. D. Boral Capital reissued a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research note on Tuesday, March 17th. Finally, UBS Group restated a “buy” rating on shares of Humacyte in a report on Monday, December 1st. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.71.

Humacyte Stock Performance

Humacyte stock opened at $0.68 on Friday. The firm has a fifty day simple moving average of $1.04 and a two-hundred day simple moving average of $1.28. The company has a quick ratio of 0.90, a current ratio of 1.62 and a debt-to-equity ratio of 2.97. Humacyte has a twelve month low of $0.67 and a twelve month high of $2.93. The company has a market capitalization of $126.52 million, a PE ratio of -3.38 and a beta of 1.89.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Friday, March 27th. The company reported ($0.13) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.13). The company had revenue of $0.47 million for the quarter, compared to the consensus estimate of $1.35 million. Research analysts expect that Humacyte will post -1.27 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Beacon Pointe Advisors LLC raised its position in Humacyte by 28.6% during the 2nd quarter. Beacon Pointe Advisors LLC now owns 36,000 shares of the company’s stock valued at $75,000 after purchasing an additional 8,000 shares during the last quarter. Concurrent Investment Advisors LLC grew its position in shares of Humacyte by 16.6% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 59,615 shares of the company’s stock worth $104,000 after buying an additional 8,500 shares during the last quarter. SG Americas Securities LLC grew its position in shares of Humacyte by 50.3% in the 4th quarter. SG Americas Securities LLC now owns 34,075 shares of the company’s stock worth $33,000 after buying an additional 11,411 shares during the last quarter. Independent Advisor Alliance increased its stake in shares of Humacyte by 49.4% during the third quarter. Independent Advisor Alliance now owns 36,240 shares of the company’s stock valued at $63,000 after buying an additional 11,991 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey increased its stake in shares of Humacyte by 74.1% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 30,774 shares of the company’s stock valued at $64,000 after buying an additional 13,101 shares during the period. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Trending Headlines about Humacyte

Here are the key news stories impacting Humacyte this week:

• Positive Sentiment: D. Boral Capital reaffirmed a “buy” rating and set an outsized $25.00 price target, signaling strong upside expectations from that firm. Benzinga
• Positive Sentiment: Humacyte named Rick McElheny SVP of Business Development to expand collaborations and commercialization efforts—management hire aimed at accelerating partnerships that could drive future revenue. GlobeNewswire: Appointment
• Neutral Sentiment: Full earnings call transcript is available for investors wanting management commentary and Q&A that could clarify outlook and commercial plans. Earnings Call Transcript
• Negative Sentiment: Q4 results: GAAP loss of ($0.13) per share met consensus, but revenue came in at roughly $0.47–0.5M versus analyst expectations near $1.35M (and full‑year sales only $2.0M). The revenue shortfall and low near-term sales reduce near-term visibility and likely pressured the stock. MarketBeat: Earnings Press Release Zacks
• Negative Sentiment: BTIG reduced its price target from $6.00 to $3.00 (still a “buy”), signaling a more cautious near-term outlook from another sell-side firm and lowering consensus upside. Benzinga

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.